Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 22;14(9):2097.
doi: 10.3390/cancers14092097.

Improving Patients' Life Quality after Radiotherapy Treatment by Predicting Late Toxicities

Affiliations
Review

Improving Patients' Life Quality after Radiotherapy Treatment by Predicting Late Toxicities

Ariane Lapierre et al. Cancers (Basel). .

Abstract

Personalized treatment and precision medicine have become the new standard of care in oncology and radiotherapy. Because treatment outcomes have considerably improved over the last few years, permanent side-effects are becoming an increasingly significant issue for cancer survivors. Five to ten percent of patients will develop severe late toxicity after radiotherapy. Identifying these patients before treatment start would allow for treatment adaptation to minimize definitive side effects that could impair their long-term quality of life. Over the last decades, several tests and biomarkers have been developed to identify these patients. However, out of these, only the Radiation-Induced Lymphocyte Apoptosis (RILA) assay has been prospectively validated in multi-center cohorts. This test, based on a simple blood draught, has been shown to be correlated with late radiation-induced toxicity in breast, prostate, cervical and head and neck cancer. It could therefore greatly improve decision making in precision radiation oncology. This literature review summarizes the development and bases of this assay, as well as its clinical results and compares its results to the other available assays.

Keywords: biomarkers; late toxicities prediction; personalized treatment; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

D. Azria declares NovaGray, stock options. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Figures

Figure 1
Figure 1
RILA assay procedure (adapted from Brengues et al. [36]).
Figure 2
Figure 2
Main hypotheses for RILA molecular rationale.

Similar articles

Cited by

References

    1. Delaney G., Jacob S., Featherstone C., Barton M. The role of radiotherapy in cancer treatment. Cancer. 2005;104:1129–1137. doi: 10.1002/cncr.21324. - DOI - PubMed
    1. Emami B., Lyman J., Brown A., Cola L., Goitein M., Munzenrider J.E., Shank B., Solin L.J., Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1991;21:109–122. doi: 10.1016/0360-3016(91)90171-Y. - DOI - PubMed
    1. Bentzen S.M., Constine L.S., Deasy J., Eisbruch A., Jackson A., Marks L.B., Haken R.T., Yorke E.D. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific Issues. Int. J. Radiat. Oncol. 2010;76:S3–S9. doi: 10.1016/j.ijrobp.2009.09.040. - DOI - PMC - PubMed
    1. Baumann M. Impact of Endogenous and Exogenous Factors on Radiation Sequelae. In: Dunst J., Sauer R., editors. Late Sequelae in Oncology. Springer; Berlin/Heidelberg, Germany: 1995. pp. 3–12. - DOI
    1. Holthusen H. Erfahrungen über die Verträglichkeitsgrenze für Röntgenstrahlen und deren Nutzanwendung zur Verhütung von Schäden. Strahlentherapie. 1936;57:254–269.

LinkOut - more resources